According to a recent meta-analysis, the use of MAO-B inhibitors as adjunct therapy to levodopa in the early stages of PD enables a reduction in levodopa dose of about 30 mg/day, but no difference in the frequency of dyskinesias was recorded compared with placebo [27]. This evidence concerns the gene MAOB and Dyskinesia.